Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing

Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing

Blog Article

Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European Union and other jurisdictions.In Spain, the 100% academic anti-CD19 CART-cell product varnimcabtagene autoleucel (var-cel, ARI-0001 cells) has been extraordinarily Your Immune approved under the Hospital Exemption clause for the treatment of patients older than 25 years of age with R/R acute lymphoblastic leukaemia.Var-cel has also been granted PRIority MEdicines designation by the European Medicines Agency for the same indication.In this Disposables - Clearance review we reveal some practical aspects related to the preparation and administration of academic point-of-care CART-cell products, using var-cel as an example, and put them into the context of commercial products.